"Founded in 2012, Lakes Research is a multi-specialty physician group with headquarters located in Miami Lakes, FL. Dedicated to patient safety and providing quality research and protocol adherence, we specialize in the completion of d phase II-IV clinical trials. Throughout the years, our ability to deliver aggressive, time bound enrollment goals, while providing trustworthy data to pharmaceutical companies and CROs, has earned Lakes Research a distinguished reputation within the research industry. We conduct research studies for a large variety of medical specialties including family practice, internal medicine, hematology, oncology, rheumatology, pediatrics, nephrology, and wound care among others."

During the past decade, Lakes Research conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 14 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 12 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lakes Research" #1 sponsor was "Apellis Pharmaceuticals, Inc." with 3 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Novartis Pharmaceuticals" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lakes Research" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Lakes Research" are "Breast Cancer" (4 trials), "Systemic Lupus Erythematosus" (4 trials), "Cold Agglutinin Disease" (2 trials), "Neutropenia" (2 trials) and "Warm Autoimmune Hemolytic Anemia" (2 trials). Many other conditions were trialed in "Lakes Research" in a lesser frequency.

Most popular intervention types in "Lakes Research" are "Drug" (29 trials), "Other" (5 trials), "Biological" (3 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Pegcetacoplan" (3 trials), "Baricitinib" (2 trials), "Cyclophosphamide" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Lakes Research" are 30 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Lakes Research". undefined are not yet recruiting, 8 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Lakes Research, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Lakes Research, 3 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".